Bionano Genomics (NASDAQ:BNGO) Stock Price Up 4.3% – Here’s Why

Posted by Geri Gentry on Sep 1st, 2026

Bionano Genomics, Inc. (NASDAQ:BNGO – Get Free Report) shares traded up 4.3% during mid-day trading on Monday . The stock traded as high as $1.22 and last traded at $1.22. Approximately 177,373 shares were traded during mid-day trading, an increase of 20% from the average daily volume of 147,298 shares. The stock had previously closed at $1.17.

Wall Street Analyst Weigh In

BNGO has been the topic of several recent research reports. Weiss Ratings cut Bionano Genomics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, August 18th. Wall Street Zen raised shares of Bionano Genomics to a “hold” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $6.00.

Get Our Latest Stock Report on Bionano Genomics

Bionano Genomics Trading Up 4.3%

The firm has a market capitalization of $14.37 million, a price-to-earnings ratio of -0.40 and a beta of 1.63. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.96. The firm’s 50-day simple moving average is $1.15 and its 200 day simple moving average is $1.17.

Bionano Genomics (NASDAQ:BNGO – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.03. Bionano Genomics had a negative return on equity of 78.78% and a negative net margin of 106.58%.The firm had revenue of ($6.67) million for the quarter, compared to the consensus estimate of $7.55 million. Equities analysts expect that Bionano Genomics, Inc. will post -2.49 earnings per share for the current year.

Institutional Trading of Bionano Genomics

Large investors have recently bought and sold shares of the business. DRW Securities LLC bought a new stake in shares of Bionano Genomics during the 4th quarter valued at approximately $258,000. GSA Capital Partners LLP acquired a new position in Bionano Genomics during the 2nd quarter worth approximately $170,000. Geode Capital Management LLC lifted its stake in Bionano Genomics by 148.8% in the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after purchasing an additional 39,928 shares during the last quarter. Renaissance Technologies LLC bought a new position in Bionano Genomics in the 4th quarter valued at approximately $57,000. Finally, Jane Street Group LLC acquired a new stake in Bionano Genomics in the fourth quarter valued at approximately $34,000. 11.35% of the stock is owned by institutional investors and hedge funds.

About Bionano Genomics

(Get Free Report)

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.